Dog models for blinding inherited retinal dystrophies

Human Gene Therapy Clinical Development

Volumn 26, Issue 1, 2015, Pages 15-26

  Petersen Jones, Simon M ^a   Komáromy, András M ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLINDNESS; CANINE MODEL; COLOR BLINDNESS; ELECTRORETINOGRAPHY; GENE MUTATION; GENE THERAPY; LEBER CONGENITAL AMAUROSIS; MACULAR DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RETINA DYSTROPHY; RETINITIS PIGMENTOSA; ANIMAL; COLOR VISION DEFECTS; DISEASE MODEL; DOG; GENETICS; HUMAN; RETINAL DYSTROPHIES;

CANIS FAMILIARIS;

CIS TRANS ISOMERASE; RETINOID ISOMEROHYDROLASE;

ANIMALS; BLINDNESS; CIS-TRANS-ISOMERASES; COLOR VISION DEFECTS; DISEASE MODELS, ANIMAL; DOGS; GENETIC THERAPY; HUMANS; LEBER CONGENITAL AMAUROSIS; MACULAR DEGENERATION; RETINAL DYSTROPHIES;

EID: 84965089562     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2014.155     Document Type: Article

References (113)

1. Mowat FM, Petersen-Jones SM, Williamson H, et al. Topographical characterization of cone photoreceptors and the area centralis of the canine retina. Mol Vis 2008; 14:2518-2527.
2. Beltran WA, Cideciyan AV, Guziewicz KE, et al. Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations. PLoS One 2014;9:e90390.
3. Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol 2004;49:379-398.
4. Stone EM. Leber congenital amaurosis-a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol 2007;144:791-811.
5. Den Hollander AI, Roepman R, Koenekoop RK, et al. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 2008;27:391-419.
6. Jin M, Li S, Moghrabi WN, et al. Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 2005; 122:449-459.
7. Redmond TM, Poliakov E, Yu S, et al. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA 2005;102:13658-13663.
8. Wang JS, Estevez ME, Cornwall MC, et al. Intra-retinal visual cycle required for rapid and complete cone dark adaptation. Nat Neurosci 2009;12:295-302.
9. Jacobson SG, Aleman TS, Cideciyan AV, et al. Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci USA 2007;104:15123-15128.
10. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 2010;29:398-427.
11. Narfstrom K, Wrigstad A, Nilsson SE. The briard dog: a new animal model of congenital stationary night blindness. Br J Ophthalmol 1989;73:750-756.
12. Wrigstad A, Nilsson SE, Narfström K. Ultrastructural changes of the retina and the retinal pigment epithelium in briard dogs with hereditary congenital night blindness and partial day blindness. Exp Eye Res 1992;55:805-818.
13. Wrigstad A, Narfström K, Nilsson SE. Slowly progressive changes of the retina and retinal pigment epithelium in briard dogs with hereditary retinal dystrophy. A morphological study. Doc Ophthalmol 1994;87:337-354.
14. Veske A, Nilsson SE, Narfström K, et al. Retinal dystrophy of Swedish briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics 1999;57:57-61.
15. Aguirre GD, Baldwin V, Pearce-Kelling S, et al. Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect. Mol Vis 1998;4:23.
16. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-95.
17. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAVmediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005;12:1072-1082.
18. Aguirre GK, Komaromy AM, Cideciyan AV, et al. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 2007;4:e230.
19. Jacobson SG, Acland GM, Aguirre GD, et al. Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther 2006; 13:1074-1084.
20. Narfstrom K, Katz ML, Bragadottir R, et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci 2003;44:1663-1672.
21. Narfström K, Katz ML, Ford M, et al. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered 2003;94:31-37.
22. Ford M, Bragadottir R, Rakoczy PE, et al. Gene transfer in the RPE65 null mutation dog: relationship between construct volume, visual behavior and electroretinographic (ERG) results. Doc Ophthalmol 2003;107:79-86.
23. Le Meur G, Stieger K, Smith AJ, et al. Restoration of vision in RPE65-deficient briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 2007;14:292-303.
24. Jacobs JB, Dell'osso LF, Hertle RW, et al. Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci 2006;47:2865-2875.
25. Dejneka NS, Surace EM, Aleman TS, et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 2004;9:182-188.
26. Pang JJ, Chang B, Kumar A, et al. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 2006;13:565-572.
27. Lai CM, Yu MJ, Brankov M, et al. Recombinant adenoassociated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescue. Genet Vaccines Ther 2004;2:3.
28. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358:2231-2239.
29. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
30. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-990.
31. Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropologymeets geneticmedicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther 2010;21:1749-1757.
32. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010;18: 643-650.
33. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009;20:999-1004.
34. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24.
35. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009;374: 1597-1605.
36. Ashtari M, Cyckowski LL, Monroe JF, et al. The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 2011;121:2160-2168.
37. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra15.
38. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 2013;120:1283-1291.
39. Melillo P, Pecchia L, Testa F, et al. Pupillometric analysis for assessment of gene therapy in Leber congenital amaurosis patients. Biomed Eng Online 2012;11:40.
40. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008;105:15112-15117.
41. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 2013;110:E517-E525.
42. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009;361:725-727.
43. Annear MJ, Mowat FM, Bartoe JT, et al. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65. Hum Gene Ther 2013;24:883-893.
44. Mowat F, Occelli L, Gervais K, et al. Rapid photoreceptor degeneration in the area centralis and visual streak of Rpe65-deficient dogs: morphologic and histologic characterization. ARVO Meet Abstr 2013;54:1776.
45. Mowat FM, Breuwer AR, Bartoe JT, et al. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs. Gene Ther 2013;20:545-555.
46. Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med 2010;2: 21ra16.
47. Annear MJ, Bartoe JT, Barker SE, et al. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function. Gene Ther 2011;18:53-61.
48. RetNet, www.sph.uth.tmc.edu/RetNet
49. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006;368:1795-1809.
50. Aguirre GD, Rubin LF. Rod-cone dysplasia (progressive retinal atrophy) in Irish setters. J Am Vet Med Assoc 1975;166:157-164.
51. Tuntivanich N, Pittler SJ, Fischer AJ, et al. Characterization of a canine model of autosomal recessive retinitis pigmentosa due to a PDE6a mutation. Invest Ophthalmol Vis Sci 2009;50:801-813.
52. Suber ML, Pittler SJ, Quin N, et al. Irish setter dogs affected with rod-cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene. Proc Natl Acad Sci USA 1993;90:3968-3972.
53. Petersen-Jones SM, Entz DD, Sargan DR. cGMP phos-phodiesterase-a mutation causes progressive retinal atrophy in the Cardigan Welsh corgi dog. Invest Ophthalmol Vis Sci 1999;40:1637-1644.
54. Petit L, Lheriteau E, Weber M, et al. Restoration of vision in the pde6beta-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther 2012;20:2019-2030.
55. Gaub BM, Berry MH, Holt AE, et al. Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci USA 2014;111:E5574-E5583.
56. Mowat FM, Bartoe JT, Bruewer A, et al. Evaluation of rod photoreceptor function and preservation following retinal gene therapy in the PDE6a mutant dog. ARVO Meet Abstr 2012;53:1928.
57. Kijas JW, Cideciyan AV, Aleman TS, et al. Naturally occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. Proc Natl Acad Sci USA 2002;99: 6328-6333.
58. Cideciyan AV, Jacobson SG, Aleman TS, et al. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci USA 2005;102:5233-5238.
59. Zhu L, Jang GF, Jastrzebska B, et al. A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor. J Biol Chem 2004;279:53828-53839.
60. Komaromy AM, Acland GM, Aguirre GD. Operating in the dark: a night-vision system for surgery in retinas susceptible to light damage. Arch Ophthalmol 2008;126: 714-717.
61. Iwabe S, Genini S, Sudharsan R, et al. Assessment of AAV-mediated RHO augmentation in the canine T4R RHO model of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2014;55:3316.
62. Gorbatyuk MS, Aguirre GD, Acland GM, et al. Molecular therapeutic approaches for treatment of autosomal dominant RP (ADRP) in a canine T4R rhodopsin model. Invest Ophthalmol Vis Sci 2003;44:2341.
63. Wright RN, Hong DH, Perkins B. Misexpression of the constitutive Rpgr(ex1-19) variant leads to severe photoreceptor degeneration. Invest Ophthalmol Vis Sci 2011; 52:5189-5201.
64. Zeiss CJ, Acland GM, Aguirre GD. Retinal pathology of canine X-linked progressive retinal atrophy, the locus homologue of RP3. Invest Ophthalmol Vis Sci 1999;40: 3292-3304.
65. Zhang Q, Acland GM, Wu WX, et al. Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum Mol Genet 2002; 11:993-1003.
66. Beltran WA, Cideciyan AV, Lewin AS, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 2012;109:2132-2137.
67. Beltran WA, Cideciyan AV, Lewin AS, et al. Gene augmentation for X-linked retinitis pigmentosa caused by mutations in RPGR. Cold Spring Harb Perspect Med 2014;pii:a017392.
68. Beltran WA, Cideciyan AV, Lewin AS, et al. RPGR gene augmentation delivered at early, mid and late stage disease in a canine model of XLRP rescues photoreceptor structure and function. Invest Ophthalmol Vis Sci 2014; 55:3321.
69. Mellersh CS, Boursnell ME, Pettitt L, et al. Canine RPGRIP1 mutation establishes cone-rod dystrophy in miniature longhaired dachshunds as a homologue of human Leber congenital amaurosis. Genomics 2006;88:293-301.
70. Miyadera K, Kato K, Aguirre-Hernandez J, et al. Phenotypic variation and genotype-phenotype discordance in canine cone-rod dystrophy with an RPGRIP1 mutation. Mol Vis 2009;15:2287-2305.
71. Kuznetsova T, Iwabe S, Boesze-Battaglia K, et al. Exclusion of RPGRIP1 ins44 from primary causal association with early-onset cone-rod dystrophy in dogs. Invest Ophthalmol Vis Sci 2012;53:5486-5501.
72. Miyadera K, Kato K, Boursnell M, et al. Genome-wide association study in RPGRIP1(-/-) dogs identifies a modifier locus that determines the onset of retinal degeneration. Mamm Genome 2012;23:212-223.
73. Kuznetsova T, Zangerl B, Goldstein O, et al. Structural organization and expression pattern of the canine RPGRIP1 isoforms in retinal tissue. Invest Ophthalmol Vis Sci 2011;52:2989-2998.
74. Lheriteau E, Petit L, Weber M, et al. Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy. Mol Ther 2014;22:265-277.
75. Turney C, Chong NH, Alexander RA, et al. Pathological and electrophysiological features of a canine cone-rod dystrophy in the miniature longhaired dachshund. Invest Ophthalmol Vis Sci 2007;48:4240-4249.
76. Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. Br J Ophthalmol 2004;88:291-297.
77. Sidjanin DJ, Lowe JK, Mcelwee JL, et al. Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. Hum Mol Genet 2002;11:1823-1833.
78. Yeh CY, Goldstein O, Kukekova AV, et al. Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. BMC Genet 2013;14:27.
79. Komaromy AM, Rowlan JS, Corr AT, et al. Transient photoreceptor deconstruction by CNTF enhances rAAVmediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther 2013;21:1131-1141.
80. Komaromy AM, Alexander JJ, Cooper AE, et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther 2008;15: 1049-1055.
81. Komaromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010;19:2581-2593.
82. Garcia MM, Ying GS, Cocores CA, et al. Evaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs. Am J Vet Res 2010; 71:97-102.
83. Carvalho LS, Xu J, Pearson RA, et al. Long-term and agedependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011;20:3161-3175.
84. Tao W, Wen R, Goddard MB, et al. Encapsulated cellbased delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292-3298.
85. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006;103: 3896-3901.
86. Wen R, Song Y, Kjellstrom S, et al. Regulation of rod phototransduction machinery by ciliary neurotrophic factor. J Neurosci 2006;26:13523-13530.
87. Banin E, Obolensky A, Ejzenberg A, et al. Gene therapy in a sheep model of CNGA3 achromatopsia. Invest Ophthalmol Vis Sci 2014;55:4566.
88. Zobor D, Stanzial F, Kellner U, et al. Retinal structure and function in achromatopsia: the CNGA3 phenotype. Invest Ophthalmol Vis Sci 2014;55:346.
89. Guziewicz KE, Zangerl B, Lindauer SJ, et al. Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for best disease. Invest Ophthalmol Vis Sci 2007;48:1959-1967.
90. Zangerl B, Wickstrom K, Slavik J, et al. Assessment of canine BEST1 variations identifies new mutations and establishes an independent bestrophinopathy model (cmr3). Mol Vis 2010;16:2791-2804.
91. Guziewicz KE, Zangerl B, Komaromy AM, et al. Recombinant AAV-mediated BEST1 transfer to the retinal pigment epithelium: analysis of serotype-dependent retinal effects. PLoS One 2013;8:e75666.
92. Guziewicz K, Komaromy A, Iwabe S, et al. Sustained therapeutic reversal of canine bestrophinopathy with gene therapy using recombinant AAV2. Invest Ophthalmol Vis Sci 2013;54:5965.
93. Guziewicz K, Beltran W, Cideciyan A, et al. Gene therapy for bestrophinopathies. Acta Ophthalmol 2014;92.
94. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 2008;16:458-465.
95. Jacobs JB, Dell'osso LF, Hertle RW, et al. Gene therapy to abolish congenital nystagmus in RPE65-deficient canines. Invest Ophthalmol Vis Sci 2003;44:4249.
96. Jacobs JB, Dell'osso LF,Wang ZI, et al. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci 2009;50:4685-4692.
97. Narfström K, Bragadottir R, Redmond TM, et al. Functional and structural evaluation after AAV.RPE65 gene transfer in the canine model of Leber's congenital amaurosis. Adv Exp Med Biol 2003;533:423-430.
98. Narfström K, Seeliger M, Lai CM, et al. Morphological aspects related to long-term functional improvement of the retina in the 4 years following rAAV-mediated gene transfer in the RPE65 null mutation dog. Adv Exp Med Biol 2008;613:139-146.
99. Narfström K, Vaegan, Katz M, et al. Assessment of structure and function over a 3-year period after gene transfer in RPE65-/- dogs. Doc Ophthalmol 2005;111:39-48.
100. Petersen-Jones SM, Annear MJ, Bartoe JT, et al. Gene augmentation trials using the Rpe65-deficient dog: contributions towards development and refinement of human clinical trials. Adv Exp Med Biol 2012;723:177-182.
101. Dekomien G, Runte M, Godde R, et al. Generalized progressive retinal atrophy of sloughi dogs is due to an 8-bp insertion in exon 21 of the PDE6B gene. Cytogenet Cell Genet 2000;90:261-267.
102. Goldstein O, Mezey JG, Schweitzer PA, et al. IQCB1 and PDE6B mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds. Invest Ophthalmol Vis Sci 2013;54:7005-7019.
103. Kukekova AV, Goldstein O, Johnson JL, et al. Canine RD3 mutation establishes rod-cone dysplasia type 2 (rcd2) as ortholog of human and murine rd3. Mamm Genome 2009;20:109-123.
104. Goldstein O, Kukekova AV, Aguirre GD, et al. Exonic SINE insertion in STK38l causes canine early retinal degeneration (erd). Genomics 2010;96:362-368.
105. Downs LM, Wallin-Hakansson B, Boursnell M, et al. A frameshift mutation in golden retriever dogs with progressive retinal atrophy endorses SLC4A3 as a candidate gene for human retinal degenerations. PLoS One 2011;6: e21452.
106. Winkler PA, Ekenstedt KJ, Occelli LM, et al. A large animal model for CNGB1 autosomal recessive retinitis pigmentosa. PLoS One 2013;8:e72229.
107. Goldstein O, Jordan JA, Aguirre GD, et al. A non-stop S-antigen gene mutation is associated with late onset hereditary retinal degeneration in dogs. Mol Vis 2013;19: 1871-1884.
108. Zangerl B, Goldstein O, Philp AR, et al. Identical mutation in a novel retinal gene causes progressive rod-cone degeneration in dogs and retinitis pigmentosa in humans. Genomics 2006;88:551-563.
109. Downs LM, Bell JS, Freeman J, et al. Late-onset progressive retinal atrophy in the Gordon and Irish setter breeds is associated with a frameshift mutation in C2orf71. Anim Genet 2012;44:169-177.
110. Goldstein O, Mezey JG, Boyko AR, et al. An ADAM9 mutation in canine cone-rod dystrophy 3 establishes homology with human cone-rod dystrophy 9. Mol Vis 2010; 16:1549-1569.
111. Wiik AC, Wade C, Biagi T, et al. A deletion in nephronophthisis 4 (NPHP4) is associated with recessive cone-rod dystrophy in standard wire-haired dachshund. Genome Res 2008;18:1415-1421.
112. Dutrow EV, Tanaka N, Miyadera K, et al. A missense mutation in canine CNGA3 eliminates retinal cone function: a novel model for achromatopsia. Invest Ophthalmol Vis Sci 2014;55:1641.
113. Dekomien G, Vollrath C, Petrasch-, Parwez E, et al. Progressive retinal atrophy in schapendoes dogs: mutation of the newly identified ccdc66 gen. Neurogenetics 2010; 11:163-174.